Primary signet ring cell adenocarcinoma of the bladder accounts for less than 1 per cent of all primary bladder neoplasms. This tumor is insidious because of its subepithelial infiltrative nature ...

What are the signs and symptoms of bladder cancer, and what are its risk factors? Here's what you need to know, according to an expert.

High-risk, non-muscle-invasive bladder cancer is defined as any transitional cell carcinoma (TCC) of the bladder that is high-grade, whether it is primary or recurrent. This high-risk group ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Early signals from an ongoing study at The Christie Hospital in Manchester shore up the evidence for an investigational treatment for the most common form of bladder cancer (urothelial carcinoma).

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The proteomic landscape of muscle-invasive bladder cancer (MIBC) in the context of platinum-based neoadjuvant chemotherapy (NAC) remains to be explored. Here, proteomic analysis of MIBC tumours ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...